Search Results

Q BioMed Inc. provides an update to shareholders.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2024 financial results and provided a business update.

The new research team at the BioMed X Institute in Heidelberg will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

Orchestra BioMed Holdings, Inc. announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 4-6, 2024.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced further details on its in-person R&D day at the Lotte New York Palace Hotel on Tuesday, June 11, 2024, at 10:00 AM ET.

Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the patent estate related to AVIM Therapy has reached 110 patents worldwide.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2023 financial results and provided a fourth quarter business update.

Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024.

Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the appointment of David Pacitti to its Board of Directors, effective as of March 26, 2024.

Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains that closely mirror the one recently detected in cows, chickens and one person in Texas.